Skip to main content

Advertisement

SpringerLink
Log in

The effect of corticosteroid therapy on cyclooxygenase 2, vascular endothelial growth factor, and inducible nitric oxide synthase expression levels in nasal polyposis

  • Rhinology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Nasal and oral corticosteroid therapy is the ultimate treatment for sinonasal polyposis. Although there are numerous clinical studies regarding the factors associated with the formation of nasal polyposis, there is not enough literature on how these factors are influenced by steroid treatment. Twenty-one patients that had no prior medical therapy for nasal polyposis or had received medical therapy at least 6 months earlier were included in the study. Patients were treated with oral and nasal corticosteroid therapy. Nasal polyp biopsies were taken before and after medical treatment and immunohistochemical staining for cyclooxygenase 2 (COX-2), vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were applied to the specimens. In this study, we tried to demonstrate the effects of corticosteroid therapy on nasal polyposis tissue immunohistochemically. There was no change at immunohistochemical expression level of COX-2; however, the decline of immunohistochemical expression levels of VEGF and iNOS was statistically significant. Short-term steroid therapy does not affect COX-2 level of the nasal polyposis tissue, but has an influence on iNOS and VEGF levels. Our findings were harmonious with those of the previous studies of the literature. Further studies are needed to demonstrate the long-term effects with a larger patient group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Settipane GA (1996) Epidemiology of nasal polyps. Allergy Asthma Proc 17(5):231–236

    CAS  PubMed  Google Scholar 

  2. Tos M, Sasaki Y, Ohnishi M, Larsen P, Drake-Lee AB (1992) Fireside conference 2. Pathogenesis of nasal polyps. Rhinol Suppl 14:181–185

    CAS  PubMed  Google Scholar 

  3. Andrews AE, Bryson JM, Rowe-Jones JM (2005) Site of origin of nasal polyps: relevance to pathogenesis and management. Rhinology 43:180–184

    CAS  PubMed  Google Scholar 

  4. Fokkens WJ, Lund V, Bachert C et al (2005) European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl 18:1–87

    Google Scholar 

  5. Aouad RK, Chiu AG (2011) State of the art treatment of nasal polyposis. Am J Rhinol Allergy 25(5):291–298

    PubMed  Google Scholar 

  6. Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181–F191

    CAS  PubMed  Google Scholar 

  7. Demoly P, Crampette L, Lebel B, Campbell AM, Mondain M, Bousquet J (1998) Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa. Clin Exp Allergy 28(3):278–283

    CAS  PubMed  Google Scholar 

  8. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, Mullol J (1999) Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 160(1):291–296

    CAS  PubMed  Google Scholar 

  9. Yun CB, Lee BH, Jang TJ (2002) Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients. Ann Otol Rhinol Laryngol 111(1):61–67

    PubMed  Google Scholar 

  10. Roca-Ferrer J, Pujols L, Gartner S, Moreno A, Pumarola F, Mullol J, Cobos N, Picado C (2006) Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax 61(7):592–596

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Owens JM, Shroyer KR, Kingdom TT (2008) Expression of cyclooxygenase and lipoxygenase enzymes in sinonasal mucosa of patients with cystic fibrosis. Arch Otolaryngol Head Neck Surg 134(8):825–831

    PubMed  Google Scholar 

  12. Pujols L, Benitez P, Alobid I, Martinez-Antón A, Roca-Ferrer J, Mullol J, Picado C (2009) Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo. Eur Respir J 33(3):502–508

    CAS  PubMed  Google Scholar 

  13. Roca-Ferrer J, Garcia–Garcia FJ, Pereda J, Perez-Gonzalez M, Pujols L, Alobid I, Mullol J, Picado C (2011) Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol 128(1):66–72

    CAS  PubMed  Google Scholar 

  14. Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5):1029–1039 (Review)

    CAS  PubMed Central  PubMed  Google Scholar 

  15. Ito A, Hirota S, Mizuno H, Kawasaki Y, Takemura T, Nishiura T, Kanakura Y, Katayama Y, Nomura S, Kitamura Y (1995) Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation. Pathol Int 45(10):715–720

    CAS  PubMed  Google Scholar 

  16. Coste A, Brugel L, Maître B, Boussat S, Papon JF, Wingerstmann L, Peynègre R, Escudier E (2000) Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor. Eur Respir J15(2):367–372

    Google Scholar 

  17. Wittekindt C, Hess A, Bloch W, Sultanie S, Michel O (2002) Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol 259(6):294–298

    PubMed  Google Scholar 

  18. Yang J, Dong Z, Kong H, Guan G, Yang Z (2002) Expression and significance of the vascular permeability factor in nasal polyps. Chin Med J (Engl) 115(8):1251–1252

    Google Scholar 

  19. Jiang S, Dong Z, Zhu D, Yang Z (2003) Local tissue hypoxia and formation of nasal polyps. Chin Med J (Engl) 116(2):243–247

    Google Scholar 

  20. Gosepath J, Brieger J, Lehr HA, Mann WJ (2005) Expression, localization, and significance of vascular permeability/vascular endothelial growth factor in nasal polyps. Am J Rhinol 19(1):7–13

    PubMed  Google Scholar 

  21. Hu KH, Lee FP, Cheng YJ, Huang HM (2007) Vascular endothelial growth factor and children featuring nasal polyps. Int J Pediatr Otorhinolaryngol 71(1):23–28

    PubMed  Google Scholar 

  22. Lee HS, Myers A, Kim J (2009) Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J Respir Crit Care Med 180(11):1056–1067. doi:10.1164/rccm.200905-0740OC

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Park SK, Kim HI, Yang YI (2009) Roles of vascular endothelial growth factor, Angiopoietin 1, and Angiopoietin 2 in nasal polyp. Laryngoscope 119(2):409–413

    CAS  PubMed  Google Scholar 

  24. Blantz RC, Munger K (2002) Role of nitric oxide in inflammatory conditions. Nephron 90:373–378

    PubMed  Google Scholar 

  25. Nussler AK, Billiar TR (1993) Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 54(2):171–178 (Review)

    CAS  PubMed  Google Scholar 

  26. Ramis I, Lorente J, Roselló-Catafau J, Quesada P, Gelpí E, Bulbena O (1996) Differential activity of nitric oxide synthase in human nasal mucosa and polyps. Eur Respir J 9(2):202–206

    CAS  PubMed  Google Scholar 

  27. Watkins DN, Lewis RH, Basclain KA, Fisher PH, Peroni DJ, Garlepp MJ, Thompson PJ (1998) Expression and localization of the inducible isoform of nitric oxide synthase in nasal polyp epithelium. Clin Exp Allergy 28(2):211–219

    CAS  PubMed  Google Scholar 

  28. Parikh A, Scadding GK, Gray P, Belvisi MG, Mitchell JA (2002) High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics. Acta Otolaryngol 122(3):302–305

    CAS  PubMed  Google Scholar 

  29. Dötsch J, Puls J, Klimek T, Rascher W (2002) Reduction of neuronal and inducible nitric oxide synthase gene expression in patients with cystic fibrosis. Eur Arch Otorhinolaryngol 259(4):222–226

    PubMed  Google Scholar 

Download references

Conflict of interest

We have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. ENT Department, Tarsus State Hospital, İsmetpaşa Mh., 33440, Tarsus, Mersin, Turkey

    Demet Yazici

  2. ENT Department, Professor Çukurova University Medical Faculty, Adana, Turkey

    Ülkü Tuncer

  3. Pathology Department, Professor Çukurova University Medical Faculty, Adana, Turkey

    Aysun Uğuz

Authors
  1. Demet Yazici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ülkü Tuncer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aysun Uğuz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Demet Yazici.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazici, D., Tuncer, Ü. & Uğuz, A. The effect of corticosteroid therapy on cyclooxygenase 2, vascular endothelial growth factor, and inducible nitric oxide synthase expression levels in nasal polyposis. Eur Arch Otorhinolaryngol 271, 1541–1547 (2014). https://doi.org/10.1007/s00405-013-2718-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-013-2718-3

Keywords

Search

Navigation